Clinical Research Directory

Inclusion Criteria: * Diagnosis of LEBS based on clinical symptoms and in some cases histological or molecular findings * Palmar skin lesions: blisters and/or : erosions, edematous and erythematous lesions, crusts. 3 lesions per foot, as a minimum * Similar clinical severity of skin lesions on both feet * Patient with social security * Written consent of the patient * Patient able to understand the study's questionnaires Exclusion Criteria: * Patients with only one leg and a different number of toes on each foot. * Known hypersensitivity to botulinic toxin or its excipients * Current treatment with aminosides * Myasthenia * Swallowing difficulties * Respiratory disorders * Past medical history of dysphagia or pneumopathy of inhalation * Known allergy or contraindications to lidocaine, prilocaine, paracetamol or nitrous oxide * Pregnancy (positive pregnancy test (β-HCG) for women of childbearing age, performed within the 2 days prior to the study. Breastfeeding. * Contraception during 6 months from inclusion * Mental or physical or judicial incapacity to fill the questionnaires * Guardianship patients * Skin infection on the soles at the time of the inclusion * Skin lesions located on the soles, not related to LEBS (ie. post traumatic wound, wart) * Patient suffering from dishydrosis * Botulinic toxin injections in the previous 6 months * Inclusion in another study in the previous 2 months